Does probiotic supplementation improve quality of life in mild-to-moderately active ulcerative colitis patients in Jordan? A secondary outcome of the randomized, double-blind, placebo-controlled study - PubMed (original) (raw)

Randomized Controlled Trial

. 2023 Oct;62(7):3069-3077.

doi: 10.1007/s00394-023-03207-8. Epub 2023 Jul 27.

Affiliations

Randomized Controlled Trial

Does probiotic supplementation improve quality of life in mild-to-moderately active ulcerative colitis patients in Jordan? A secondary outcome of the randomized, double-blind, placebo-controlled study

Yaser Mohammed Rayyan et al. Eur J Nutr. 2023 Oct.

Abstract

Purpose: Recent findings revealed a potential effect of a probiotic in improving quality of life (QoL) in ulcerative colitis (UC). In Jordan, there is scarce data about UC patients and QoL.

Methods: Twenty-four UC patients were included in the study and were randomly allocated into probiotic (3 × 1010 probiotic capsules containing nine Lactobacillus and five Bifidobacterium species) and placebo control groups (containing polysaccharide supplied in an identical bottle) 3 times daily/6 weeks. A short inflammatory bowel disease questionnaire (SIBDQ) was used to assess the change in the quality of life in both groups at the beginning and the end of the intervention; The study was completed during the COVID-19 pandemic.

Results: Patients treated with probiotics showed a higher score of social (6.92 ± 0.29, p = 0.019), bowel (6.31 ± 0.46, p = 0.001), emotional (6.47 ± 0.46, p < 0.001), and total SIBDQ scores (6.54 ± 0.29, p < 0.001) compared to the placebo group (5.75 ± 1.57, 4.72 ± 1.34, 4.42 ± 1.67 and 4.96 ± 1.27; respectively). Also, the probiotic group had significantly better scores in the systemic, social, bowel, emotional, and total SIBDQ scores in terms of pre- to post-treatment (p < 0.001).

Conclusions: The use of probiotic therapy containing Lactobacillus and Bifidobacterium species had significantly improved the quality of life among UC patients, this was shown by the improvement in the scores of the systemic domain, social domain, bowel domain, emotional domain, and total SIBDQ. This study is part of a registered study at ClinicalTrials.gov with the number NCT04223479.

Keywords: Mild to moderate disease activity; Probiotics; Quality of life; Randomized clinical trial; Ulcerative colitis.

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Guan Q (2019) A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. https://doi.org/10.1155/2019/7247238 - DOI - PubMed - PMC
    1. Kaplan GG, Windsor JW (2021) The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 18(1):56–66 - PubMed
    1. Sairenji T, Collins KL, Evans DV (2017) An update on inflammatory bowel disease. Prim Care 44(4):673–692 - PubMed
    1. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, Sadeghi A, Nixon MR, Abdoli A, Abolhassani H (2020) The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 5(1):17–30
    1. Omran S, Barakat H, Muliira JK, McMillan S (2017) Dietary and lifestyle risk factors for colorectal cancer in apparently healthy adults in Jordanian hospitals. J Cancer Educ 32:447–453 - PubMed

Publication types

MeSH terms

LinkOut - more resources